Personalizar preferências de consentimento

Utilizamos cookies para ajudar você a navegar com eficiência e executar certas funções. Você encontrará informações detalhadas sobre todos os cookies sob cada categoria de consentimento abaixo.

Os cookies que são classificados com a marcação “Necessário” são armazenados em seu navegador, pois são essenciais para possibilitar o uso de funcionalidades básicas do site.... 

Sempre ativo

Os cookies necessários são cruciais para as funções básicas do site e o site não funcionará como pretendido sem eles. Esses cookies não armazenam nenhum dado pessoalmente identificável.

Bem, cookies para exibir.

Cookies funcionais ajudam a executar certas funcionalidades, como compartilhar o conteúdo do site em plataformas de mídia social, coletar feedbacks e outros recursos de terceiros.

Bem, cookies para exibir.

Cookies analíticos são usados para entender como os visitantes interagem com o site. Esses cookies ajudam a fornecer informações sobre métricas o número de visitantes, taxa de rejeição, fonte de tráfego, etc.

Bem, cookies para exibir.

Os cookies de desempenho são usados para entender e analisar os principais índices de desempenho do site, o que ajuda a oferecer uma melhor experiência do usuário para os visitantes.

Bem, cookies para exibir.

Os cookies de anúncios são usados para entregar aos visitantes anúncios personalizados com base nas páginas que visitaram antes e analisar a eficácia da campanha publicitária.

Bem, cookies para exibir.

#ASCO2017 Malignant hemangiopericytoma: Treatment patterns and survival

Compartilhe ►

Malignant hemangiopericytoma: Treatment patterns and survival.Sub-category:

Central Nervous System Tumors

Category:

Central Nervous System Tumors

Meeting:

2017 ASCO Annual Meeting

Abstract No:

e13520

Citation:

J Clin Oncol 35, 2017 (suppl; abstr e13520)
Author(s): Rolando Barjas, David Eric Piccioni; University of California San Diego Moores Cancer Center, La Jolla, CA; Center for Personalized Cancer Therapy and Division of Hematology and Oncology, UCSD Moores Cancer Center, San Diego, CA
Abstract Disclosures
Abstract:

Background: Hemangiopericytoma (HPC), or solitary fibrous tumor of the central nervous system (CNS), is a rare mesenchymal tumor that arises from the pericytes of the meningeal capillaries. These tumors account for less than 1% of all CNS tumors and are categorized into low-grade (WHO grade I and II) or high-grade (WHO grade III, anaplastic) neoplasms. The optimal treatment for grade III HPC is unclear. The aim of this study was to evaluate treatment patterns and survival for grade III HPC using the California Cancer Registry (CCR). Methods: Treatment and demographic data were extracted from the CCR for patients with grade III HPC of the CNS, from 1988-2010. Overall Survival (OS) was evaluated as a function of treatment (surgery, radiation or both), as well as extent of resection. Kaplan Meier survival analyses were performed for OS. Bivariate and multivariable analyses were done via cox proportional hazard regression models for all demographic and treatment variables. Results: A total of 94 patients with grade III HPC were identified from the registry. The most prevalent demographics were age > 50 years (59%), female (61%), non-Hispanic White (60%), and married (54%). 54% received radiation, and subtotal resection (STR) (63%) was the most common surgical outcome. However, survival was greatest in patients that received gross total resection (GTR) with radiation (median OS not reached). GTR/radiation (median OS not reached) demonstrated improved OS compared to STR/radiation (median OS 10.3 years; HR = 0.389, 95%CI 0.157-0.960) or GTR alone (median OS 6.6 years; HR = 0.254, 95%CI 0.073-0.880). Age < 50 (median OS 15.7 years), Asian/PI (median OS not reached) and married (median OS 9.9 years) were significant predictors of OS. In the multivariable cox model worse overall survival remained for older age (HR = 3.079, 95%CI 1.428-6.636) and divorced/widowed/separated (HR = 2.027, 95%CI 1.054-3.897) when compared to their younger and married counterparts. Conclusions: Patients that received GTR and radiation demonstrated the best long-term prognosis. Demographic analyses identified additional independent predictors of survival.